Insider Selling: Amarin Co. plc (AMRN) Insider Sells 128,257 Shares of Stock

Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 128,257 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $4.25, for a total transaction of $545,092.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amarin Co. plc (AMRN) remained flat at $$4.19 during trading hours on Thursday. 914,200 shares of the company’s stock were exchanged, compared to its average volume of 1,640,000. The stock has a market capitalization of $1,130.00, a price-to-earnings ratio of -15.52 and a beta of 0.62. Amarin Co. plc has a 52 week low of $2.81 and a 52 week high of $4.47. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63.

Amarin (NASDAQ:AMRN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. Amarin’s revenue for the quarter was up 45.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.08) earnings per share. equities research analysts anticipate that Amarin Co. plc will post -0.22 earnings per share for the current fiscal year.

A number of brokerages have recently weighed in on AMRN. Cantor Fitzgerald restated a “buy” rating and issued a $10.00 price objective on shares of Amarin in a research note on Thursday. Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. BidaskClub upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Amarin in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Amarin currently has an average rating of “Buy” and an average price target of $7.75.

Large investors have recently added to or reduced their stakes in the stock. Westside Investment Management Inc. raised its stake in Amarin by 1.1% during the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Wells Fargo & Company MN raised its stake in Amarin by 15.2% during the 2nd quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 5,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Amarin during the 3rd quarter valued at $226,000. Stevens Capital Management LP acquired a new position in Amarin during the 3rd quarter valued at $229,000. Finally, TD Asset Management Inc. acquired a new position in Amarin during the 3rd quarter valued at $285,000. Hedge funds and other institutional investors own 40.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/insider-selling-amarin-co-plc-amrn-insider-sells-128257-shares-of-stock.html.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply